AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1470243 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin solution plus crystalline infusion fluids
Number of subjects: 201
Study 1470243 — intervention group
Group type: COMPARATOR
Intervention: Crystalline infusion fluids (control group)
Number of subjects: 201
Study 6486078 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy for six months in addition to standard psychotherapy
Number of subjects: 70
Study 6486078 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy (control group)
Number of subjects: 70
Study 28873320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (RR) - SHR group (n = 10) ingested standardized extract SHR-5 (432 mg daily)
Number of subjects: 20
Study 28873320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) group (n = 10)
Number of subjects: 20
Study 29786343 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid wound dressing (treatment group)
Number of subjects: 84
Study 29786343 — intervention group
Group type: COMPARATOR
Intervention: Iodophor (control group)
Number of subjects: 84
Study 24842866 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m(2))
Number of subjects: 260
Study 24842866 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly cisplatin (100 mg/m(2))
Number of subjects: 260
Study 22872200 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.5% azithromycin twice a day for three days
Number of subjects: 67
Study 22872200 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month
Number of subjects: 67
Study 20497146 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg od for 4 weeks
Number of subjects: 134
Study 20497146 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg od for 4 weeks
Number of subjects: 134
Study 20497146 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 134
Study 25942521 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver releasing lipido-colloid contact layer (CLS) dressing for 4 weeks
Number of subjects: 102
Study 25942521 — intervention group
Group type: COMPARATOR
Intervention: Control contact layer dressing (CL) for 4 weeks
Number of subjects: 102
Study 15994710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 431
Study 15994710 — intervention group
Group type: COMPARATOR
Intervention: Lithium (target blood level: 0.6-1.2 meq/liter)
Number of subjects: 431
Study 15994710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 431
Study 15994710 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 431
Study 12696839 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized interventions
Number of subjects: 7636
Study 12696839 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions with a moderate number of sessions and a clear-cut behavioral focus
Number of subjects: 7636
Study 10904055 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lower body negative pressure (LBNP) treadmill exercise at 1.0‐1.2 body wt (58 +/‐ 2 mmHg LBNP) for 40 min per day during bed rest
Number of subjects: 7
Study 10904055 — intervention group
Group type: COMPARATOR
Intervention: Control study (no exercise)
Number of subjects: 7
Study 8604676 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium-enriched cereal
Number of subjects: 25
Study 8604676 — intervention group
Group type: COMPARATOR
Intervention: Control cereal
Number of subjects: 25
Study 1994967 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptamint
Number of subjects: 10
Study 1994967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6383113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (60-120 mg)
Number of subjects: 32
Study 6383113 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 32
Study 28868169 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 92
Study 28868169 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 92
Study 25560711 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg/d)
Number of subjects: 184
Study 25560711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (preemptive therapy)
Number of subjects: 184
Study 24103327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 910
Study 24103327 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 910
Study 22002809 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 344
Study 22002809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 19844848 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib (AstraZeneca plc)
Number of subjects: 0
Study 17051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir plus ritonavir (TPV/r)
Number of subjects: 620
Study 17051503 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted comparator protease inhibitor (CPI/r)
Number of subjects: 620
Study 12626886 — intervention group
Group type: EXPERIMENTAL
Intervention: real phenotype (r‐PHT)
Number of subjects: 201
Study 12626886 — intervention group
Group type: COMPARATOR
Intervention: virtual phenotype (v‐PHT)
Number of subjects: 201
Study 11340106 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene capsules (6 mg daily for 60 days)
Number of subjects: 0
Study 11340106 — intervention group
Group type: EXPERIMENTAL
Intervention: Puréed papaya (650 g daily for 60 days)
Number of subjects: 0
Study 11340106 — intervention group
Group type: EXPERIMENTAL
Intervention: Grated carrots (100 g daily for 60 days)
Number of subjects: 0
Study 11340106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9387206 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg daily
Number of subjects: 3500
Study 9387206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study 10150446 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-social tobacco use prevention intervention with refusal skills training
Number of subjects: 389
Study 10150446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 389
Study 3305590 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical folate (2 daily applications)
Number of subjects: 0
Study 3305590 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic folate (2 daily doses)
Number of subjects: 0
Study 3305590 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0
Study 29473355 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking (12 hours before and after operation, at specific points, 1 minute each point, once every 2 hours)
Number of subjects: 480
Study 29473355 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking
Number of subjects: 480
Study 27899407 — intervention group
Group type: EXPERIMENTAL
Intervention: Navvus microcatheter
Number of subjects: 28
Study 27899407 — intervention group
Group type: COMPARATOR
Intervention: Guidewire-only assessment
Number of subjects: 28
Study 24727022 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 (100 mg) with peginterferon and ribavirin
Number of subjects: 332
Study 24727022 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 (200 mg) with peginterferon and ribavirin
Number of subjects: 332
Study 24727022 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 (400 mg) with peginterferon and ribavirin
Number of subjects: 332
Study 24727022 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 (800 mg) with peginterferon and ribavirin
Number of subjects: 332
Study 24727022 — intervention group
Group type: COMPARATOR
Intervention: Control group (boceprevir and peginterferon and ribavirin)
Number of subjects: 332
Study 24727022 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 (400 mg) and (800 mg) with peginterferon and ribavirin
Number of subjects: 332
Study 22952407 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD) of the ilioinguinal nerve and inguinal ligament (n=18)
Number of subjects: 36
Study 22952407 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic (Bupivicaine) and steroid (Trimacinolone) injection (n=18)
Number of subjects: 36
Study 22952407 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD) without randomisation (n=10)
Number of subjects: 36
Study 21564061 — intervention group
Group type: EXPERIMENTAL
Intervention: Enactment-based sessions first, followed by therapist-centered sessions
Number of subjects: 16
Study 21564061 — intervention group
Group type: COMPARATOR
Intervention: Therapist-centered sessions first, followed by enactment-based sessions
Number of subjects: 16
Study 21564061 — intervention group
Group type: EXPERIMENTAL
Intervention: Enactment-based sessions
Number of subjects: 16
Study 21564061 — intervention group
Group type: EXPERIMENTAL
Intervention: Enactment-based sessions first
Number of subjects: 16
Study 21564061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapy process modalities
Number of subjects: 16
Study 21564061 — intervention group
Group type: EXPERIMENTAL
Intervention: Enactment-based therapy process
Number of subjects: 16
Study 19096190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54
Study 19096190 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 17073160 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin therapy
Number of subjects: 0
Study 12698764 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 60
Study 12698764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 11121917 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC (peppermint oil and caraway oil)
Number of subjects: 96
Study 11121917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9373115 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA)
Number of subjects: 80
Study 1547763 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-CR 800 mg
Number of subjects: 10
Study 1547763 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-CR 1200 mg
Number of subjects: 10
Study 1547763 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-CR 1600 mg
Number of subjects: 10
Study 1547763 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-CR (all doses)
Number of subjects: 10
Study 1547763 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-CR 800 mg, 1200 mg, 1600 mg
Number of subjects: 10
Study 1547763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2868481 — intervention group
Group type: EXPERIMENTAL
Intervention: Amobarbital
Number of subjects: 45
Study 2868481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 45
Study 2868481 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone
Number of subjects: 45
Study 2868481 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 45
Study 29941416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive visual displays
Number of subjects: 20
Study 29941416 — intervention group
Group type: COMPARATOR
Intervention: Narrative abstracts
Number of subjects: 20
Study 25893979 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketoprofen in Transfersome(®) gel (IDEA‐033) plus oral placebo
Number of subjects: 168
Study 25893979 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoprofen plus TDT 064
Number of subjects: 168
Study 25893979 — intervention group
Group type: EXPERIMENTAL
Intervention: TDT 064 plus oral placebo
Number of subjects: 168
Study 24485546 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer and Go4Life educational counseling for 24 weeks
Number of subjects: 49
Study 24485546 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer alone for the next 24 weeks
Number of subjects: 49
Study 24485546 — intervention group
Group type: COMPARATOR
Intervention: No intervention for the first 24 weeks
Number of subjects: 49
Study 24485546 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer and Go4Life based counseling for the next 24 weeks
Number of subjects: 49
Study 24485546 — intervention group
Group type: EXPERIMENTAL
Intervention: Older (80-93) subjects
Number of subjects: 49
Study 24485546 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in activity level
Number of subjects: 49
Study 24485546 — intervention group
Group type: EXPERIMENTAL
Intervention: Go4Life based exercise counseling program
Number of subjects: 49
Study 21863462 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Occupational Performance Measure (COPM)
Number of subjects: 87
Study 21863462 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 87
Study 19968904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio (nuts, plant sterols, viscous fibre, vegetable protein)
Number of subjects: 0
Study 19968904 — intervention group
Group type: COMPARATOR
Intervention: First-generation statin cholesterol-lowering medication
Number of subjects: 0
Study 18667204 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA treatment (n=7503)
Number of subjects: 14981
Study 18667204 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7478)
Number of subjects: 14981
Study 16517383 — intervention group
Group type: EXPERIMENTAL
Intervention: Active manipulations
Number of subjects: 102
Study 16517383 — intervention group
Group type: COMPARATOR
Intervention: Simulated manipulations
Number of subjects: 102
Study 16517383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 14738263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 on day 1 and day 8 and Cisplatin 80 mg/m2 on day 1, administered every 3 weeks, followed by radiotherapy after chemotherapy.
Number of subjects: 20
Study 10629570 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PMN elastase concentration in PXE(+) group
Number of subjects: 65
Study 10629570 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PMN elastase concentration in PXE(-) group
Number of subjects: 65
Study 10629570 — intervention group
Group type: COMPARATOR
Intervention: Plasma PMN elastase concentration in control group
Number of subjects: 65
Study 10629570 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha1-PI concentration in PXE(+) group
Number of subjects: 65
Study 10629570 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha1-PI concentration in PXE(-) group
Number of subjects: 65
Study 9184183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate 125 mg m(‐2) on days 1‐5 every 3 weeks, escalating to 175 mg m(‐2) from course 3 when possible
Number of subjects: 17
Study 9184183 — intervention group
Group type: COMPARATOR
Intervention: Oral etoposide
Number of subjects: 17
Study 1542832 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptamen (PEP)
Number of subjects: 16
Study 1542832 — intervention group
Group type: COMPARATOR
Intervention: Vivonex TEN (VIV)
Number of subjects: 16
Study 3891194 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride preparation 1
Number of subjects: 30
Study 3891194 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride preparation 2
Number of subjects: 30
Study 3891194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31532520 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D virtual reality models during surgical planning
Number of subjects: 92
Study 31532520 — intervention group
Group type: COMPARATOR
Intervention: Usual preoperative planning with computed tomography and/or magnetic resonance imaging only
Number of subjects: 92
Study 28213673 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 45
Study 28213673 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 45
Study 25412591 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 73
Study 25412591 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 73
Study 25412591 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM girls
Number of subjects: 73
Study 25412591 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM boys
Number of subjects: 73
Study 25412591 — intervention group
Group type: COMPARATOR
Intervention: Control boys
Number of subjects: 73
Study 25412591 — intervention group
Group type: COMPARATOR
Intervention: Control girls
Number of subjects: 73
Study 25412591 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM group
Number of subjects: 73
Study 24222839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ivabradine (5 mg bolus over 30 s, followed by 5 mg infusion over 8 h)
Number of subjects: 124
Study 24222839 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 124
Study 24222839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ivabradine
Number of subjects: 124
Study 24222839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 21695122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 760
Study 21695122 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 760
Study 21695122 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 760
Study 19323633 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of clindamycin or a first-generation cephalosporin (initially intravenously for the first 2-4 days)
Number of subjects: 130
Study 19323633 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 days of clindamycin or a first-generation cephalosporin (initially intravenously for the first 2-4 days)
Number of subjects: 130
Study 16934042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 2.5 microg kg(‐1) min(‐1)
Number of subjects: 17
Study 16934042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 7.5 microg kg(‐1) min(‐1)
Number of subjects: 17
Study 16934042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15039684 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 102
Study 15039684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10778243 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 30
Study 10778243 — intervention group
Group type: COMPARATOR
Intervention: Popular music
Number of subjects: 30
Study 10778243 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 9471916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX) prophylaxis
Number of subjects: 42
Study 9471916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CNS prophylaxis)
Number of subjects: 42
Study 7682007 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 16
Study 7682007 — intervention group
Group type: COMPARATOR
Intervention: Psychopharmacological medication (withdrawn)
Number of subjects: 16
Study 4036935 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3 x 325 mg tablets)
Number of subjects: 60
Study 4036935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1 x 600 mg tablet)
Number of subjects: 60
Study 4036935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 identical placebo tablets)
Number of subjects: 60
Study 4036935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (3 ounces of 100 proof vodka diluted in 6 ounces of orange juice)
Number of subjects: 60
Study 4036935 — intervention group
Group type: COMPARATOR
Intervention: Alcohol placebo (3 ounces of water diluted in orange juice)
Number of subjects: 60
Study 30898632 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate cream (GTN)
Number of subjects: 100
Study 28263383 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP plus MC (n = 139)
Number of subjects: 422
Study 28263383 — intervention group
Group type: COMPARATOR
Intervention: MAP alone (n = 157)
Number of subjects: 422
Study 25724645 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.25 mg/kg orally
Number of subjects: 11
Study 25724645 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.125 mg/kg intravenously
Number of subjects: 11
Study 23245993 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β(2)-agonists (SABA)
Number of subjects: 32
Study 23245993 — intervention group
Group type: COMPARATOR
Intervention: Muscarinic antagonists (SAMA)
Number of subjects: 32
Study 21680723 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic computer-generated, evidence-based feedback based on questionnaire responses
Number of subjects: 465
Study 21680723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 465
Study 21680723 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 465
Study 18573663 — intervention group
Group type: EXPERIMENTAL
Intervention: Permitting slight knee flexion
Number of subjects: 21
Study 18573663 — intervention group
Group type: COMPARATOR
Intervention: Maintaining knee in total extension
Number of subjects: 21
Study 15979655 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potentials (ERPs) during a trial-by-trial task-switching version of the Stroop task
Number of subjects: 0
Study 15979655 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory capacity measure
Number of subjects: 0
Study 14688498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 0
Study 14688498 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 14688498 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 10364864 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 160
Study 10364864 — intervention group
Group type: COMPARATOR
Intervention: droperidol (1.25 mg)
Number of subjects: 160